Recursion Announces
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
05 sept. 2023 07h59 HE | Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
IMC Logo.jpg
Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)
09 août 2017 08h30 HE | Immuron Limited
Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA...
TOMI.jpg
SteraMist™ Contributes to Substantial Reduction in Clostridium Difficile Burden in Hospital
03 avr. 2017 16h05 HE | TOMI Environmental Solutions, Inc.
BEVERLY HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination and infection prevention company that specializes in...
TOMI.jpg
TOMI™ Takes Lead on Fight Against C. diff With “List K” Listing
13 mars 2017 08h00 HE | TOMI Environmental Solutions, Inc.
BEVERLY HILLS, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (TOMI) (OTCQX:TOMZ), As Clostridium Difficile Spores (C. diff) continue to plague hospitals around the...
OpenBiome logo
Fecal transplant pills: Large-scale production begins
28 oct. 2015 08h39 HE | OpenBiome
BOSTON, Oct. 28, 2015 (GLOBE NEWSWIRE) -- A new pill created by a team of MIT-trained researchers provides fecal transplant therapy without requiring the traditional, more invasive stool delivery...
Stellar Biotechnologies Presents at Annual 2013 National Science Foundation Conference
28 mai 2013 09h00 HE | Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - May 28, 2013) -  Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at...
Stellar Biotechnologies Announces Publication of "Expert Review" Article on Clostridium Difficile Vaccines
30 avr. 2013 09h00 HE | Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwired - Apr 30, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of Keyhole...
Stellar Biotechnologies Announces Exclusive Option to License Clostridium Difficile Technology
10 avr. 2012 09h05 HE | Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Apr 10, 2012) - Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) today announced that it has entered into an...